SCHEMBL14439211

SCHEMBL14439211

CC(=O)N1CCCC[C@@H]1C

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.58
GAA P10253 1/20 0.58
ALDH1A1 P00352 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.46
CHRM2 P08172 10/20 0.46
CHRM4 P08173 10/20 0.46
CHRM5 P08912 10/20 0.46
CHRM1 P11229 10/20 0.46
CHRM3 P20309 10/20 0.46
POLB P06746 1/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7888486 1.00 HPGD (0.58) HPGDGAAALDH1A1SMN1; SMN2CHRM2
SCHEMBL420108 1.00 HPGD (0.58) HPGDGAAALDH1A1SMN1; SMN2CHRM2
SCHEMBL3436833 0.93
SCHEMBL6097894 0.93
SCHEMBL419842 0.93
Propane SCHEMBL7055719 0.86 HPGD (0.46) HPGDGAAALDH1A1SMN1; SMN2CHRM2
Benzene SCHEMBL9854132 0.86 HPGD (0.50) HPGDGAAALDH1A1SMN1; SMN2POLB
SCHEMBL4028484 0.84 HPGD (0.60) HPGDGAAALDH1A1SMN1; SMN2POLB
SCHEMBL17464820 0.83
SCHEMBL14436404 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365561-A1 BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) 2023-11-16 US disclosed
CN-115701996-A Combination of a CBP/p300 bromodomain inhibitor and an EGFR inhibitor for the treatment of EGFR mutant NSCLC 托雷莫治疗股份公司 2023-02-14 CN disclosed
WO-2019075252-A1 PEPTIDOMIMETIC PROTEASOME INHIBITORS CORNELL UNIVERSITY (US) 2019-04-18 WO disclosed
US-20070203184-A1 Novel Indolin-2-one Derivatives, Their Preparation and the Pharmaceutical Compositions Comprising Them SANOFI-AVENTIS (FR) 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203184-A1 Novel Indolin-2-one Derivatives, Their Preparation and the Pharmaceutical Compositions Comprising Them OXTR, AVPR2, AVPR1B HPGD 791/4885GAA 4876/4885ALDH1A1 4275/4885
US-20230365561-A1 BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION MGAM, LCT, GANAB HPGD 873/4885GAA 4/4885ALDH1A1 315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.